© Borgis - Postępy Nauk Medycznych 1/2010, s. 92-98
Bogna Grygiel-Górniak1, *Marian Grzymisławski2
Powikłania wątrobowo-żółciowe w intensywnym leczeniu żywieniowym
Hepatobiliary complications in intensive nutrition therapy
1Katedra i Zakład Bromatologii Uniwersytetu Medycznego w Poznaniu
Kierownik Katedry: prof. dr hab. farm. Juliusz Przysławski
2Katedra i Klinika Chorób Wewnętrznych, Metabolicznych i Dietetyki
Kierownik Kliniki: prof. dr hab. med. Marian Grzymisławski
Żywienie dojelitowe zapewnia odpowiednią podaż składników pokarmowych lub umożliwia ich zwiększenie w przypadku gdy żywienie doustne jest niewystarczające. Całkowite żywienie pozajelitowe jest skuteczną metodą leczenia dostarczającą energii i składników odżywczych w sytuacji gdy żywienie doustne lub dojelitowe jest niemożliwe lub przeciwwskazane. Niemniej jednak obydwa sposoby leczenia żywieniowego, nawet jeśli umożliwiający przeżycie pacjentom będącym w ciężkim stanie, nie są pozbawione działań ubocznych. W niniejszym opracowaniu przedstawiony jest przegląd piśmiennictwa dotyczący powikłań hepatologicznych związanych z żywieniem enteralnym i parenteralnym. Zaprezentowano również diagnostykę oraz metody zapobiegania i leczenia przewlekłych powikłań wątrobowych.
Enteral nutrition is (EN) offers the possibility to increase or to insure nutrient intake in case of insufficient oral food intake. Total parenteral nutrition is an effective method for supplying energy and nutrients when oral or enteral feeding is impossible or contraindicated. However, both therapies, even life-saving of patients at critical condition in intensive care unit (ICU), are not avoided of clinical and epidemiological complications. Herein we reviewed data regarding the enteral and parenteral nutrition-related hepatobiliary complications. Diagnostic evaluation, preventive suggestions and therapies for chronic hepatobiliar complications are also presented in this review.
The patients at intensive care unit (ICU) usually required one of two major nutritional supports enteral (EN) or parenteral therapy (PN) (1, 2, 3). Parenteral nutrition is a life-saving therapy that provides the necessary complete and balanced nutrition for patients who are unable to absorb sufficient nutrients due to intestinal abnormalities or in which there is a contraindication to use the gastrointestinal (GI) tract (insufficient intestinal length or function) (2). From the first time, in the 1960s, when the total parenteral nutrition was implemented many varies studies were conducted to estimate its application and possible side effects (1, 3, 4).
Clinical and epidemiological data indicate that total parenteral nutrition may be associated with a variety of problems. One of the major causes of morbidity and mortality of patients receiving long-term total parenteral nutrition are liver diseases (5). Hepatobiliary system can be affected and complications may vary from mildly elevated liver enzyme values to steatosis, steatohepatitis, cholestasis, cholelithiasis, fibrosis and cirrhosis (4, 6, 7). The most common of these is parenteral nutrition-associated cholestasis (PNAC), that may progress to liver failure (5, 6, 7).
Conversely to parenteral nutrition, enteral food supplying by means of oral nutritional supplements (ONS) and tube feeding (TF) offers the possibility to increase or to insure nutrient intake in case of insufficient oral food intake. This kind of nutritional therapy is indicated when patients cannot meet their caloric requirements through normal food and when there are no contraindications fromm gastrointestinal track (ex., ileus). Enteral nutrition, even not so often as parenteral nutrition, may cause also sides effects including liver damage (3).
The incidence of total parenteral nutrition-related hepatobiliary complications has been reported to be very high, ranging from 20 are to 75% in adults (4). Approximately 40-60% of children on long-term PN will develop hepatic dysfunction (8). In particular, total parenteral nutrition is considered to be an absolute nutrition-related risk factor for the development of biliary sludge and gallstones and is often associated with hepatic steatosis and intrahepatic cholestasis (4). Also hypertriglyceridemia is a common complication predisposing to hepatiobilary complications and it occurs in up to 33% of patients receiving PN (1).
Enteral and parenteral nutritional therapy may be related to transient elevations of liver enzyme concentrations, which return to normal level after parenteral nutrition is discontinued (3, 4). However, long-term use of PN is also associated with more deleterious sides effects including bloodstream infections and metabolic abnormalities. The most severe complication – end-stage liver disease has been described in approximately 15-20% of patients receiving prolonged total intra-venous nutrition (5).
HEPATOBILIARY DISORDERS ASSOCIATED WITH PARENTERAL NUTRITION
Prolonged parenteral nutrition therapy associated with hepatobiliary disorders is commonly called parenteral nutrition associated liver disease – PNALD. It is the most prevalent and simultaneously most severe complication of intra-venous nutrition (1).
PNALD is characterized by elevations of serum aminotransferases, bilirubin, and alkaline phosphatase. Histologic alterations include steatosis, steatohepatitis, and cholestasis and, in some cases, progresses to fibrosis and cirrhosis (2). It is the most devastating complication of long-term parenteral nutrition therapy. The serum aminotransferase concentrations usually increases, however the increase is minor and does not require intervention (1). Unfortunately its progression is typically insidious causing the late diagnosis, when liver injury is irreversible. If the end-stage liver disease (ESLD) develops, medical treatment is usually futile, and only viable intervention in such stage is the transplantation of both an intestine and a liver (9, 10).
Although likely multifactorial in origin, the etiology of PNALD is poorly understood. A number of causes of PNALD have been proposed, including clinical intervention, nutrient deficiencies and excesses or individual features. Factors that contributes to PNALD include are presented in table 1.
Table 1. Risk factors of PNALD development (1, 2).
|Etiologic factors contributing to PNALD development|
|Clinical factors||? bacterial sepsis|
? bacterial overgrowth
? long-term use of parenteral nutrition
? absence of enteral nutrition
? gastrointestinal mucosal disease
? prolonged diverting enterostomies
? multiple operative procedures
? length of intestinal resection
|Individual factors||? young age|
? premature birth
? low birth weight
|Nutrient deficiencies||? taurine|
? essential fatty acids
? vitamin E
|Nutrient excesses ||? energy|
? amino acids
|Other nutritional factors||? excessive calorie intake|
? dextrose-to-lipid ratio
? amino acid dose
? intra-venous fat emulsion (IVFE) dose
? continuous vs cyclic infusion
GENETIC FACTORS OF PNALD
Genetic factors should be also consider in the pathophysiological mechanism of PNALD. Multidrug resistance 1 gene (mdr1) and mdr2 seem to the main factor responsible for hepatobiliary condition. These genes encode P-glycoproteins that are bile canalicular transport proteins carrying bile components out of hepatocytes. In animal model the lack of mdr2 expression develop liver disease that appears similar to PNALD. Not only the decline in mdr2 but also the rise in mdr1 mRNA and protein expression with total parenteral nutrition administration occur before the development of liver injury (during an early state of cholestasis). This suggests that alterations in multidrug resistance genes expression may be a causative factor in the development of PNALD (11).
The possible cause of fatty liver development is a combination of various metabolic processes affecting lipid metabolism, such as increased mobilization from depot fat, augmented synthesis in liver, increased transport to liver, impaired transport from liver, and decreased oxidation of fatty acids (12). The histological examination reveal macro- or micro-vesicular hepatic steatosis with ballooned, fatty degeneration of hepatocytes (13).
Clinical and animal studies suggest that the development of steatosis associated with parenteral nutrition may be caused by apoptotic processes – the main mechanism stimulating fat deposition in the liver (2, 13, 14, 15, 16, 17, 18, 19). Apoptosis is activated through the Fas pathway. Fas is a transmembrane receptor protein belonging to the TNF receptor family and contains a death domain that signals via apoptotic pathways.
Increased levels of Fas in hepatocytes were recently reported in subjects with steatosis and impaired liver function (13, 18). Also lipids are a causative factors in oxidative stress, which are expressed via Fas-mediated apoptosis. In animal model Fas upregulation induced by PN were associated by other markers of hepatocytes apoptosis that included lower ATP concentration, accumulation of ubiquitin, activation of caspase-3 activity, and increased cleavage of poly-(ADP-ribose) polymerase, caspase-8, -9, and -7 (13).
Increased lipid peroxidation and apoptosis of hepatocytes may be caused by short-term as well as long-term PN (17). Continuous administration of PN may result in decreased oxidative phosphorylation in the hepatic mitochondria, leading to speculation that this deterioration in mitochondrial function may contribute to hepatic dysfunction (14). Lipids may also induces the mitochondrial-mediated apoptosis (Bcl-2 interactions) and seem to be a causative factor of fat accumulation in the hepatocytes. Bcl-2 and proliferating cell nuclear antigen expression are downregulated during this processes (13).
The fact that apoptotic changes of hepatocytes may induce the steatosis was also confirm in clinical conditions including nonalcoholic steatohepatitis (NASH) and alcoholic fatty liver disease (AFLD) (15, 16). Moreover, parenteral nutrition induced steatosis may also suppress the ability of hepatocytes to regenerate. It was proved that steatotic liver grafts are associated with a high incidence of primary non-function and initial poor function (19).
PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS (PNAC)
Parenteral nutrition-associated cholestasis is the most common complication of PN affecting hepatobiliary system. Bowel rest and bile stasis during parenteral nutrition lead to production of sludge, which can result in eventual gallstone formation (6, 20). The primary indicator of cholestasis is a serum conjugated bilirubin>2 mg/dl (1).
Whereas steatosis is relatively more common in adults, cholestasis is the most common and predictable parenteral nutrition-associated hepatobiliary dysfunction in children (2, 10). Nevertheless, pathologic background of PNAC is poorly understood. Its etiology is multifactorial and include excessive caloric administration, parenteral nutrition components, and nutritional deficiencies. Risk factors include prematurity, long duration of parenteral nutrition, sepsis, lack of bowel motility, and short bowel syndrome (2, 12).
The study of Messing et al. indicated that the percentage of sludge-positive patients during parenteral nutrition increased from 6% during the first three weeks to 50% after the fourth week in the group of 23 patients without hepatobiliary complication before nutritional treatment. Gallstone formation was observed only in sludge-forming patients but did not appeared in patients who were sludge-negative. Three of the 6 first stone-forming patients underwent cholecystectomy because of complications secondary to cholelithiasis after a mean 43-day course of parenteral nutrition. However the sludge positivity decreased during the first three weeks oral indicated refeeding (6).
ESSENTIAL FATTY ACIDS DEFICIENCY (EFAD)
Essential fatty acids (EFA) cannot be synthesized in human tissues and must be obtained from the diet. Many evidence indicates that unsaturated acids originating from plant oils in lipid emulsions may play a role in the onset of liver injury. The currently approved parenteral lipid emulsions contain safflower or soybean oils. Both oils are reach in omega -6 polyunsaturated fatty acids (PUFAs) that reveals potential proinflammatory effect (22). Omega-6 fatty acid presented in the commercial emulsions are not cleared and targeted similarly to enteral chylomicrons that are rapidly combined with apolipoproteins from HDL and transported to liver. Molecules formed during omega-6 fatty acids parenteral ingestion accumulate in the liver and are not so effective as in limiting de novo lipogenesis. This way they contribute to a steatosis of the liver that became more susceptible to oxidative injury (23).
Conversely to omega-6 fatty acids the omega-3 EFA reveal the antyinflammatory effect. This effect is mainly caused by the changes of the arachidonic acid pathway. Omega-3 polyunsaturated fatty acids displace arachidonic acid from tissue fatty acid pools and thereby reducing the substrate for eicosanoid-synthesizing enzymes and subsequent inflammation (24). They are especially beneficial in liver diseases (steathosis) because they participate in lipid metabolism and reduce elevated cholesterol and triglycerides. Deficiency can develop when intake of EFAs is insufficient (<1%-2% of total calories), that happened during the use of PN with inadequate fat intake (25).
The mechanism of omega-3 fatty acid clearance is independent from the route of administration (parenteral or enteral). Omega-3 fatty acid emulsions decrease lipogenesis de novo and prevent or ameliorate hepatosteatosis induced by parenteral nutrition in animal model. Especially eicosapentaenoic acid is one of the any fatty acid that reveals the greatest reduction of triglyceride production in the liver (21, 26).
Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.
Płatny dostęp do wszystkich zasobów Czytelni Medycznej
1. Kumpf VJ: Parenteral nutrition-associated liver disease in adult and pediatric patients. Nutr Clin Pract 2006; 21: 279-90.
2. Colomb V Jobert- Giraud A, Lacaille F et al: Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. JPEN J Parenter Enteral Nutr 2000; 24: 345-50.
3. Plauth M, Merli M, Kondrup J et al.: ESPEN Guidelines on enteral nutrition: liver disease. Clin Nutr 2006; 25: 285-94.
4. Guglielmi FW, Boggio-Bertinet D, Frederico A et al.: Total parenteral nutrition-related gastroenterological complications. Dig Liver Dis 2006; 38: 623-42.
5. Buchman AL: Complications of long-term home total parenteral nutrition: their identification, prevention and treatment. Dig Dis Sci. 2001; 46: 1-18.
6. Messing B, Bories C, Kunstlinger F et al.: Does total parenteral nutrition induce gallbladder sludge formation and lithiasis? Gastroenterology 1983; 84: 1012-19.
7. Maitreyi R, Johane PA: Parenteral nutrition related hepato-biliary disease in adults. Appl Physiol Nutr Metab 2007; 32: 646-54.
8. Kelly DA: Liver complications of pediatric parenteral nutrition-epidemiology. Nutrition 1998; 14: 153-7.
9. Buchman AL, Jyer K, Fryer J: Parenteral nutrition-associated liver disease and the role for isolated intestine and intestine/liver transplantation.. Hepatology 2006; 43: 9-19.
10. Meehan JJ, Georgeson KE: Prevention of liver failure in parenteral nutrition-dependent children with short bowel syndrome. J Pediatr Surg 1997, 32: 473-75.
11. Tazuke Y, Kiristioglu J, Heidelberger KP et al.: Hepatic P-glycoprotein changes with total parenteral nutrition administration. JPEN J Parenter Enteral Nutr 2004; 28: 1-6.
12. Zambrano E, El-Hennawy M, Ehrenkranz RA et al.: Total parenteral nutrition induced liver pathology: an autopsy series of 24 newborn cases. Pediatr Dev Pathol 2004; 7: 425-32.
13. Wang H, Khaoustov VJ, Krishnan B et al.: Total parenteral nutrition induces liver steatosis and apoptosis in neonatal piglets. American Society for Nutrition. J Nutr 2006; 136: 2547-52.
14. Katayama T, Tanaka M, Tanaka K et al.: Alterations in hepatic mitochondrial function during total parenteral nutrition in immature rats. JPEN J Parenter Enteral Nutr 1990; 14: 640-5.
15. Ribeiro PS, Cortez-Pinto H, Solá S et al.: Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99: 1708-17.
16. Feldstein AE, Canbay A, Angulo P et al.: Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-43.
17. Tazuke Y, drongowski RA, Btaiche J et al.: Effects of lipid administration on liver apoptotic signals in a mouse model of total parenteral nutrition (TPN). Pediatr Surg Int 2004; 20: 224-8.
18. Minana JB, Górnez-Cambronero L, Lloret A et al.: Mitochondrial oxidative stress and CD95 ligand: a dual mechanism for hepatocyte apoptosis in chronic alcoholism. Hepatology 2002; 35: 1205-14.
19. Marsman WA, Wiesner RH, Rodriguez L et al.: Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996; 62: 1246-51.
20. Boland GW, Slater G, Lu DS et al.: Prevalence and significance of gallbladder abnormalities seen on sonography in intensive care unit patients. AJR Am J Roentgenol. 2000; 174: 973-7.
21. Van Aerde JE, Duerksen DR, Gramlich L et al.: Intravenous fish oil emulsion attenuates total parenteral nutrition-induced cholestasis in newborn piglets. Pediatr Res 1999; 45: 202-8.
22. de Meijer VE, Gura KM, Le HD et al.: Fish oil-based lipid emulsions prevent and reverse parenteral nutrition – associated liver disease: the Boston experience. JPEN J Parenter Enteral Nutr 2009; 33: 541-47.
23. Day CP, James OF: Steatohepatitis: a tale of two „hits”? Gastroenterology 1998; 114: 842-5.
24. Bellenger J, Bellenger S, Clement L et al.: A new hypotensive polyunsaturated fatty acid dietary combination regulates oleic acid accumulation by suppression of stearoyl CoA desaturase 1 gene expression in the SHR model of genetic hypertension. FASEB J 2004; 18: 773-5.
25. Fleming CR et al.: Essential fatty acid deficiency in adults receiving total parenteral nutrition. Am J Clin Nutr 1976; 29: 976-83.
26. Araya J, Rodrigo R, Videla LA et al.: Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in non-alcoholic fatty liver disease patients. Clin Sci (Lond) 2004; 106: 635-43.
27. Siguel EN: Criteria for essential fatty acid deficiency in plasma as assessed by capillary column gas-liquid chromatography. Clin Chem 1987; 33:1869-73.
28. Alwayn IP, Gura K, Nose V et al.: Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res 2005; 57: 445-52.
29. Sugiura T, tashiro T, Yamamori H et al.: Effects of total parenteral nutrition on endotoxin translocation and extent of the stress response in burned rats. Nutrition 1999; 15: 570-5.
30. Javid PJ, Collier S, Richardson Det al.: The role of enteral nutrition in the reversal of parenteral nutrition-associated liver dysfunction in infants. J Pediatr Surg 2005; 40: 1015-18.
31. Richardson RA et al.: Enteral nutrition and liver function test abnormalities . J Hum Nutr Diet 2009; 1: 227-32.
32. Stehle P: Development of liver dysfunction dunder artificial nutrition: a reason to modyfy nutrition therapy In the intestine care unit? Critical Care 2007; 11: 112-113.
33. Qing-Gang H, Qi-Chang Z: The influence of Enteral Nutrition in postoperative patients with poor liver function. World J Gastroenterol 2003; 9: 843-6.
34. Zhu L, Yang ZC, Li A et al.: Protective effect of early enteral feeding on postburn impairment of liver function and its mechanism in rats. World J Gastroenterol 2000; 6: 79-83.
35. Fulford A, Scolapio JS, Aranda-Michel J: Parenteral-nutrition associated hepatotoxicity. Nutr Clin Pract 2004; 21: 279-290.
36. López-Herce J, Mencia S, Sánchez C et al.: Postpyloric enteral nutrition in the critically ill child with shock: a prospective observational study. Nutr J 2008; 7: 6.
37. Diamond IR, Pencharz PB, Wales PW et al.: Omega-3 lipids for intestinal failure associated liver disease. Semin Pediatr Surg 2009; 18: 239-45.
38. Gura KM, Parsons SK, Bechard LJ et al.: Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition. Clin Nutr 2005; 24: 839-47.
39. Hallikainen M, Huikko L, Kontra K et al.: Effect of Parenteral Serum Plant Sterols on Liver Enzymes and Cholesterol Metabolism in a Patient With Short Bowel Syndrome. Nutr Clin Pract 2008; 23: 429-35.
40. Gura K, Strijbosch R, Arnold S et al.: The role of an intravenous fat emulsion composed of fish oil in a parenteral nutrition-dependent patient with hypertriglyceridemia. Nutr Clin Pract 2007; 22: 664-72.
41. Llop J, Sabin P, Garau M et al.: Hospital Pharmacy Artificial Nutrition Group of Catalonia. The importance of clinical factors in parenteral nutrition-associated hypertriglyceridemia. Clin Nutr 2003; 22: 577-83.
42. Kowdley KV: Ursodeoxycholic acid therapy in hepatobiliary disease. Am J Med 2000; 108: 481-6.